• Organization TypeIndependent/None, Service Providers
  • Staff101-250
  • HeadquartersUnited States
  • Founded2000

Immatics Biotechnologies

ABOUT Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Their transformative product candidates are - best in class - Adoptive Cell Therapies and TCR Bispecific molecules TCER™. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology. Their mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients. COMPANY HISTORY Privately-held Immatics was established in 2000 as a spin out from H.G. Rammensee's laboratory at the University of Tübingen, Germany. The Company was founded to develop and commercialize ground-breaking discoveries on the immunopeptidome as targets for all types of T-cell based immunotherapies. In 2015, Immatics and MD Anderson Cancer Center (MDACC) launched Immatics US, Inc. in Houston, Texas as a joint venture to develop transformative Adoptive Cell Therapies.
See more

Company Offices

  • United States (headquarters)
  • 2130 W. Holcombe Blvd., Suite 900 Houston, Texas
  • Germany
  • Machtlfinger Str. 11 81379 Munich Germany
  • Germany
  • Paul-Ehrlich-Str. 15 72076 Tuebingen Germany